Seattle Genetics announces FDA approval of ADCETRIS® (brentuximab vedotin)
Seattle Genetics announced the FDA has approved ADCETRIS (brentuximab vedotin) in combination with chemotherapy in adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma. The approval is based on the successful outcome of the phase 3 ECHELON-1 clinical trial. March 20, 2018